NCT05940961 Phase 2
Recruiting
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Enrollment
42 pts
Location
China
Sponsor
Sheng-Li Xue, MD
NCT06131801
Recruiting
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Enrollment
30 pts
Location
United States
Sponsor
Children's Hospital Medical Ce...